Quantum Biopharma Ltd (QNTM) Stock Price, Quote & News

Company Profile

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company's lead compound is Lucid-MS, a patented new chemical enti...

Industry: Biotechnology

Sector: Healthcare

Phone: 833 571 1811

Website: www.quantumbiopharma.com

Address:

1 Adelaide Street East, Suite 801, Toronto, Canada

NetworkNewsWire Sep. 10 at 1:12 PM

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market $QNTM $NVS $MRK $TGTX $BMY https://ibn.fm/A7zHr

1 · Reply

MrTicker Sep. 10 at 12:30 PM

$QNTM Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market GLOBENEWSWIRE 7:30 AM ET 9/10/2026

1 · Reply

FickleFin Sep. 10 at 12:04 PM

$QNTM pump and dump. Exit liquidity. Why do you think Baloney is trying so hard...

0 · Reply

ThebullishWick Sep. 9 at 11:16 PM

Ticker SGLY could be the next low float hidden monster market sends. -SGLY recently announced a strategic pivot toward AI infrastructure. -Low borrow/600% CTB/Massive book value near $17! $MVIS $PRZO $QNTM $GCDT . :).

0 · Reply

Woodman7 Sep. 9 at 2:47 PM

$BIIB $CLNN $QNTM $RHHBY $SNY From the article: “Clene Inc. (NASDAQ: CLNN) shared results from new analyses examining clinical outcomes among CNM-Au8(R)-treated patients whose neurofilament light chain (“NfL”) biomarker levels declined or stabilized. These findings will be included in Clene’s planned New Drug Application (“NDA”) seeking accelerated approval and are intended to address the questions raised by the U.S. Food and Drug Administration (“FDA”) during a March 2026 Type C meeting. At that meeting, the FDA acknowledged that NfL, a recognized blood marker of nerve-cell injury, has established prognostic value in amyotrophic lateral sclerosis (“ALS”) and could potentially serve as a reasonably likely surrogate endpoint to support accelerated approval.”

0 · Reply

MrTicker Sep. 9 at 2:08 PM

$QNTM $4+ on tap

1 · Reply

NetworkNewsWire Sep. 9 at 1:58 PM

BioMedNewsBreaks — $QNTM $QNTM.CN Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial https://ibn.fm/dwwiP

0 · Reply

FickleFin Sep. 9 at 1:06 PM

$QNTM $GNS $GME this is literally their PEA story all over again. The hype the bunk press releases. Partnership with 3rd party to accelerate studies. Mass pumping, mass paid promo. Then you have baloney that adds to the mess. What ever happened to the naked short lawsuit? They sure went quiet with that. All this company is.. is noise and press releases. Only lemmings invest in shitcos

0 · Reply

MrTicker Sep. 9 at 12:32 PM

$QNTM Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment GLOBENEWSWIRE 7:30 AM ET 9/9/2026

0 · Reply

Stock_Catcher Sep. 9 at 12:32 PM

$QNTM Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

0 · Reply

Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

Tue, 01 Sep 2026 19:00:00 -0400 - 8 days ago

Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange

2026-08-31T11:10:12.000Z - 10 days ago

Quantum Group initiated with a Buy at Rodman & Renshaw

Fri, 21 Aug 2026 19:00:00 -0400 - 19 days ago

Quantum Biopharma Provides Corporate Update

Fri, 14 Aug 2026 07:00:00 -0400 - 27 days ago

Quantum BioPharma Strengthens Equity and Liquidity in Q2 2026 as FDA Approves Lucid-MS for Pivotal Phase 2 Clinical Trial

Mon, 10 Aug 2026 07:00:00 -0400 - 4 weeks ago

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

Thu, 30 Jul 2026 00:18:00 -0400 - 6 weeks ago

Quantum BioPharma Announces Closing of Debt Settlement

Mon, 20 Jul 2026 19:00:00 -0400 - 7 weeks ago

Quantum BioPharma Announces Intention to Settle Debt

Tue, 07 Jul 2026 19:00:00 -0400 - 2 months ago

Quantum BioPharma Provides Corporate Update

Fri, 26 Jun 2026 08:30:00 -0400 - 2 months ago

NetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple Sclerosis

Thu, 25 Jun 2026 08:30:00 -0400 - 2 months ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS Therapy

Tue, 23 Jun 2026 08:30:00 -0400 - 2 months ago

Quantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different Approach

Tue, 02 Jun 2026 08:00:00 -0400 - 3 months ago

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.

Tue, 02 Jun 2026 07:40:00 -0400 - 3 months ago

Quantum BioPharma Engages Stocks.news For Investor Relations, Marketing Services And Lead Generation Campaigns

Mon, 01 Jun 2026 19:30:00 -0400 - 3 months ago

Quantum BioPharma Provides Corporate Update

Mon, 18 May 2026 03:00:00 -0400 - 3 months ago

Quantum BioPharma Reaches Key Midpoint Milestone in Groundbreaking Imaging Study with Massachusetts General Hospital

Thu, 07 May 2026 07:00:00 -0400 - 4 months ago

Quantum Reports Strengthened Liquidity, Reduced Cash Burn, and Disciplined Cost Management in First Quarter 2026

Mon, 27 Apr 2026 19:45:00 -0400 - 4 months ago

Quantum BioPharma Provides Corporate Update

Wed, 22 Apr 2026 09:16:00 -0400 - 4 months ago

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Appoints Richard Buzbuzian as CEO to Lead Nationwide Commercialization of Innovative, Clinically Validated Hangover Remedy and Alcohol Metabolism Accelerant

2026-04-01T12:25:14.000Z - 5 months ago

Quantum BioPharma submits Lucid-21-302 new drug application to the FDA

Wed, 01 Apr 2026 08:02:00 -0400 - 5 months ago

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

2026-03-30T12:47:57.000Z - 5 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

2026-03-30T12:28:19.000Z - 5 months ago

Quantum BioPharma signs letter of intent with Allucent to conduct Lucid-MS trial

Mon, 30 Mar 2026 07:50:00 -0400 - 5 months ago

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Fri, 27 Mar 2026 19:30:00 -0400 - 5 months ago

Quantum Biopharma Provides Corporate Update

Fri, 27 Mar 2026 08:10:00 -0400 - 5 months ago

Quantum Biopharma's 2025 Audited Year End Financial Results Maintain ‘No Going Concern' Status

Mon, 23 Mar 2026 08:24:00 -0400 - 5 months ago

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd

Fri, 20 Mar 2026 19:35:00 -0400 - 5 months ago

Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering

Wed, 11 Mar 2026 19:55:00 -0400 - 6 months ago

Quantum BioPharma Provides Corporate Update

Thu, 19 Feb 2026 19:29:00 -0500 - 6 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Thu, 19 Feb 2026 12:00:00 -0500 - 6 months ago

Bronstein, Gewirtz & Grossman LLC Urges Quantum Biopharma Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

Tue, 17 Feb 2026 13:55:00 -0500 - 6 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 12:59:00 -0500 - 6 months ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Tue, 17 Feb 2026 09:41:00 -0500 - 6 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Thu, 12 Feb 2026 16:02:00 -0500 - 6 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - QNTM

Tue, 03 Feb 2026 13:12:00 -0500 - 7 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Mon, 02 Feb 2026 10:46:00 -0500 - 7 months ago

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma Ltd. Investors

Tue, 27 Jan 2026 13:42:00 -0500 - 7 months ago

CONTACT: INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Quantum Biopharma Ltd. of Class Action Lawsuit and Upcoming Deadlines – QNTM

Dec 23, 2025, 8:00 AM EST - 8 months ago

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)

Mon, 22 Dec 2025 09:00:00 -0500 - 8 months ago

World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares

Dec 10, 2025, 8:00 PM EST - 9 months ago

Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update

2025-12-01T12:15:18.000Z - 9 months ago

Quantum BioPharma announces airing of news segment on manipulation lawsuit

Nov 27, 2025, 4:00 PM EST - 9 months ago

Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada's Largest Banks, CIBC and RBC

Nov 26, 2025, 9:30 AM EST - 9 months ago

Quantum Biopharma's USD $700 Million Lawsuit Alleging Stock Market Manipulation Subject of 3-part Series Investigative News Program W5

2025-11-07T12:12:42.000Z - 10 months ago

Quantum BioPharma reports Q3 EPS ($1.25) vs. (4.37) last year

2025-11-07T12:11:35.000Z - 10 months ago

Quantum BioPharma sees cash runway beyond March 2027

Nov 7, 2025, 7:00 AM EST - 10 months ago

Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern' Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio

Oct 31, 2025, 7:51 PM EDT - 10 months ago

Quantum BioPharma Ltd. Provides Corporate Update

Oct 29, 2025, 9:00 PM EDT - 10 months ago

Quantum BioPharma Ltd. Announces Corporate Updates

Oct 23, 2025, 8:15 AM EDT - 10 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar for its Disruptive Beverage Innovation that Speeds Alcohol Metabolism, Reduces Symptoms of Intoxication

2025-10-20T12:40:40.000Z - 10 months ago

Quantum BioPharma announces expiration of warrants held by hedge funds

Oct 20, 2025, 8:30 AM EDT - 10 months ago

Quantum BioPharma Ltd. Announces Expiration of All Warrants Held by Hedge Funds and Re-Iterates October 27, 2025, Record Date for the Distribution of a Special Dividend

Oct 9, 2025, 6:00 PM EDT - 11 months ago

Quantum BioPharma Ltd. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – QNTM

Oct 8, 2025, 8:00 AM EDT - 11 months ago

Quantum BioPharma Announces Cash Reward of up to USD $7Million for Proof of Market Manipulation in its Stock

Oct 7, 2025, 11:00 AM EDT - 11 months ago

Quantum BioPharma: Engineering the Digital Balance Sheet in Life Sciences A Vanderbilt Report View

Oct 3, 2025, 7:00 AM EDT - 11 months ago

Quantum BioPharma Announces the Record Date for the Distribution of a Special Dividend of Contingent Value Rights (CVRs) Tied to the Future Litigation Settlement Proceeds of its USD $700 Million+ Case

Oct 2, 2025, 7:57 AM EDT - 11 months ago

Quantum BioPharma Receives Final Reports for Two Key Studies of its Potential Breakthrough Drug for Multiple Sclerosis, Moving Closer to Phase 2 Clinical Trial

Oct 1, 2025, 7:50 AM EDT - 11 months ago

Quantum BioPharma Welcomes World-Renowned Multiple Sclerosis Expert Dr. Jack Antel as Clinical Development Advisor For Lucid-MS Trials

Sep 29, 2025, 7:40 AM EDT - 11 months ago

Quantum BioPharma Ltd. Announces Results of Annual General and Special Meeting of Shareholders

Sep 26, 2025, 8:00 PM EDT - 11 months ago

Quantum BioPharma Announces Corporate Updates

Sep 24, 2025, 8:30 AM EDT - 11 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Live Webinar and Q&A Session on Wednesday, October 1, 2025

Sep 18, 2025, 8:10 AM EDT - 11 months ago

Health Canada Grants Quantum BioPharma a Product License for Its Innovative Product, Qlarity™, that Enhances Energy, and Promotes Metabolism, Mental Alertness and Cognitive Performance

Sep 12, 2025, 7:50 AM EDT - 12 months ago

Quantum BioPharma Licensee Unbuzzd Wellness to Host Investor Webinar on September 16, 2025 at 1:30 PM PT

Sep 10, 2025, 7:00 AM EDT - 1 year ago

Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target

Aug 11, 2025, 6:32 PM EDT - 1 year ago

Quantum BioPharma Announces Update to Previously Announced Private Placement

Aug 11, 2025, 7:40 AM EDT - 1 year ago

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

Aug 8, 2025, 8:00 AM EDT - 1 year ago

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

Aug 5, 2025, 7:34 AM EDT - 1 year ago

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

Aug 4, 2025, 7:33 AM EDT - 1 year ago

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

NetworkNewsWire Sep. 10 at 1:12 PM

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market $QNTM $NVS $MRK $TGTX $BMY https://ibn.fm/A7zHr

1 · Reply

MrTicker Sep. 10 at 12:30 PM

$QNTM Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market GLOBENEWSWIRE 7:30 AM ET 9/10/2026

1 · Reply

FickleFin Sep. 10 at 12:04 PM

$QNTM pump and dump. Exit liquidity. Why do you think Baloney is trying so hard...

0 · Reply

ThebullishWick Sep. 9 at 11:16 PM

0 · Reply

Woodman7 Sep. 9 at 2:47 PM

0 · Reply

MrTicker Sep. 9 at 2:08 PM

$QNTM $4+ on tap

1 · Reply

NetworkNewsWire Sep. 9 at 1:58 PM

BioMedNewsBreaks — $QNTM $QNTM.CN Featured in BioMedWire Editorial Following FDA Clearance for Lucid-MS Phase 2 Trial https://ibn.fm/dwwiP

0 · Reply

FickleFin Sep. 9 at 1:06 PM

0 · Reply

MrTicker Sep. 9 at 12:32 PM

$QNTM Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment GLOBENEWSWIRE 7:30 AM ET 9/9/2026

0 · Reply

Stock_Catcher Sep. 9 at 12:32 PM

$QNTM Quantum BioPharma Ltd. NASDAQ: QNTM) Receives FDA Clearance to Begin Trials for Historic MS Treatment

0 · Reply

parcha Sep. 8 at 5:45 PM

https://www.cnbc.com/2026/09/08/stocks-making-the-biggest-moves-midday-amgn-qcom-expe-crwv.html $QBTS $RGTI $QNTM Quantum computing stocks – The quantum computing sector rallied after the U.S. agreed to take minority equity stakes in several companies as part of a $300 million CHIPS Act deal. The investments are in D-Wave Quantum, Rigetti Computing and Quantinuum. D-Wave gained more than 7%, Rigetti rose 4% and Quantinuum added 3%.

1 · Reply

NetworkNewsWire Sep. 8 at 4:16 PM

InvestorNewsBreaks – $QNTM $QNTM.CN Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial https://ibn.fm/rxdvk

0 · Reply

NetworkNewsWire Sep. 8 at 1:04 PM

A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach $QNTM $SNY $RHHBY $BIIB $CLNN https://ibn.fm/MrHnd

0 · Reply

topstockalerts Sep. 8 at 11:36 AM

$QNTM keep an eye on it

0 · Reply

GPDL Sep. 8 at 2:19 AM

$QNTM Should get nicer volume now with just being on the nasdaq not cse

0 · Reply

topstockalerts Sep. 7 at 8:59 PM

$QNTM I wouldn’t ignore this setup

1 · Reply

JuggernautRaider Sep. 6 at 12:48 PM

$QNTM hmmmmmmm ♋️

0 · Reply

RollingPins Sep. 5 at 12:01 AM

$QNTM nice close before long weekend!!

0 · Reply

FickleFin Sep. 3 at 11:50 AM

$QNTM $GNS $GME Quantum BioPharma plans to VOLUNTARILY DELIST its Class B subordinate voting shares from the Canadian Securities Exchange, while maintaining listings on Nasdaq, the Frankfurt Stock Exchange and Upstream. **The company cites low trading volumes in Canada and the costs and regulatory burden of a dual listing as reasons to consolidate trading on Nasdaq, which it expects could support improved long-term liquidity. 🤡🥴

0 · Reply

FickleFin Sep. 3 at 11:44 AM

$QNTM $17,243,174 ATM is still active. Hence why dorkus is pumping shit stock after getting fired then rehired then fired then ignored then hired again. Leading new investors to the slaughterhouse... 🤡🥴

0 · Reply

deedee12 Sep. 2 at 1:58 AM

$QNTM 👎🏼👎🏼👎🏼👎🏼

0 · Reply

focafoca99 Sep. 2 at 12:58 AM

$QNTM has applied to voluntarily delist its Class B shares from the Canadian Securities Exchange.

0 · Reply

Market Cap	21.05M
Revenue (ttm)	0.00
Net Income (ttm)	-26.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	176,716
Avg Vol	187,026
Day's Range	N/A - N/A
Shares Out	6.40M
Stochastic %K	81%
Beta	0.45
Analysts	Strong Sell
Price Target	$21.75